Maxim Group Initiates Coverage on Rein Therapeutics (NASDAQ:RNTX)

Stock analysts at Maxim Group began coverage on shares of Rein Therapeutics (NASDAQ:RNTX) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The firm set a “buy” rating and a $4.00 price target on the stock. Maxim Group’s price target would indicate a potential upside of 347.03% from the stock’s current price.

A number of other research analysts have also weighed in on the company. HC Wainwright dropped their price objective on Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Weiss Ratings downgraded Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Finally, Wall Street Zen upgraded shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $6.00.

Rein Therapeutics Trading Up 6.0%

Shares of RNTX opened at $0.89 on Monday. Rein Therapeutics has a twelve month low of $0.83 and a twelve month high of $2.18. The stock’s 50 day moving average is $0.98 and its two-hundred day moving average is $1.19. The firm has a market capitalization of $76.54 million, a PE ratio of -0.47 and a beta of 1.35.

Rein Therapeutics (NASDAQ:RNTX) last issued its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.30. On average, sell-side analysts predict that Rein Therapeutics will post -0.53 EPS for the current year.

Hedge Funds Weigh In On Rein Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of RNTX. Susquehanna International Group LLP purchased a new stake in Rein Therapeutics during the third quarter worth $35,000. HRT Financial LP purchased a new position in shares of Rein Therapeutics in the fourth quarter valued at $38,000. Chicago Partners Investment Group LLC raised its stake in shares of Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after buying an additional 10,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Rein Therapeutics during the 2nd quarter worth $68,000. Finally, Jane Street Group LLC purchased a new stake in shares of Rein Therapeutics in the 4th quarter worth about $72,000. 90.89% of the stock is owned by institutional investors and hedge funds.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.